Next Generation Sequencing Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Next Generation Sequencing Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Report Description
Next Generation Sequencing (NGS) is a high-throughput DNA sequencing technology that separates billions or millions of DNA strands and sequence in parallel, yielding more output and reducing the need for fragment-cloning methods (Sanger sequencing of genomes). However, read lengths for NGS are shorter than Sanger due to the signal to noise ratio, which increases with read length. NGS allows simultaneous screening of mutations in large number of genes. For example, a patient with symptoms of Leigh syndrome performed exome sequencing to find candidate gene variants. Furthermore, it is used for analysis and for interpreting sequenced data, analyzing specific gene associated with the patient’s clinical condition.
Market Dynamics
Major factors driving growth of the next generation sequencing market are early detection of cancer and infectious diseases and increasing partnership among academic and industry partnerships for research and development. For academic institutions, these collaborations help in commercialization of their discoveries from basic research to medical products. For instance, in March, 2018, Cofactor Genomics, a U.S.-based developer of Cofactor Paragon (RNA analysis tool) signed agreement with National Cancer Institute, and other three other pharma and academic institutes to show clinical ability of its product.
Increasing prevalence of cancer and infectious diseases and ability of NGS platforms to detect cancers and infectious diseases are expected to drive growth of the next generation sequencing market during the forecast period. The use of NSG for study of cancer cells mutations is increasing and the implementation of this technology has considerably aided in early diagnosis of diseases. In the U.S., over 1.69 million new cancer cases were detected in 2021; whereas the global incidence of cancer was around 14 million new cases in 2012 and an annual 19.3 million cases are estimated by 2025. However, interpretation of complex data, lack of skilled professionals, and issues related to security of NGS data are expected to limit growth of the market.
Key features of the study:
This report provides in-depth analysis of next generation sequencing market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global next generation sequencing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., BioMerieux S.A., F. Hoffmann-La Roche Ltd, Qiagen N.V., Illumina, Inc., Oxford Nanopore Technologies, and Beijing Genomics Co. Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global next generation sequencing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the next generation sequencing market
Detailed Segmentation:
Global Next Generation Sequencing Market, By Technology:
Whole Genome Sequencing
Whole Exome Sequencing
RNA Sequencing
Targeted Re-sequencing
Others
Global Next Generation Sequencing Market, By Application:
Drug Discovery
Personalized Medicine and Genetic Screening
Disease Diagnosis
Agriculture and Animal Research
Others
Global Next Generation Sequencing Market, By End User:
Hospital
Research Centers
Pharma and Biotech Firms
Others
Global Next Generation Sequencing Market, By Region:
North America
By Technology:
Whole Genome Sequencing
Whole Exome Sequencing
RNA Sequencing
Targeted Re-sequencing
Others
By Application:
Drug Discovery
Personalized Medicine and Genetic Screening
Disease Diagnosis
Agriculture and Animal Research
Others
By End User:
Hospital
Research Centers
Pharma and Biotech Firms
Others
By Country:
U.S.
Canada
Latin America
By Technology:
Whole Genome Sequencing
Whole Exome Sequencing
RNA Sequencing
Targeted Re-sequencing
Others
By Application:
Drug Discovery
Personalized Medicine and Genetic Screening
Disease Diagnosis
Agriculture and Animal Research
Others
By End User:
Hospital
Research Centers
Pharma and Biotech Firms
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Technology:
Whole Genome Sequencing
Whole Exome Sequencing
RNA Sequencing
Targeted Re-sequencing
Others
By Application:
Drug Discovery
Personalized Medicine and Genetic Screening
Disease Diagnosis
Agriculture and Animal Research
Others
By End User:
Hospital
Research Centers
Pharma and Biotech Firms
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Technology:
Whole Genome Sequencing
Whole Exome Sequencing
RNA Sequencing
Targeted Re-sequencing
Others
By Application:
Drug Discovery
Personalized Medicine and Genetic Screening
Disease Diagnosis
Agriculture and Animal Research
Others
By End User:
Hospital
Research Centers
Pharma and Biotech Firms
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Technology:
Whole Genome Sequencing
Whole Exome Sequencing
RNA Sequencing
Targeted Re-sequencing
Others
By Application:
Drug Discovery
Personalized Medicine and Genetic Screening
Disease Diagnosis
Agriculture and Animal Research
Others
By End User:
Hospital
Research Centers
Pharma and Biotech Firms
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Technology:
Whole Genome Sequencing
Whole Exome Sequencing
RNA Sequencing
Targeted Re-sequencing
Others
By Application:
Drug Discovery
Personalized Medicine and Genetic Screening
Disease Diagnosis
Agriculture and Animal Research
Others
By End User:
Hospital
Research Centers
Pharma and Biotech Firms
Others
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Thermo Fisher Scientific Inc.*
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Agilent Technologies, Inc.
BioMerieux S.A.
F. Hoffmann-La Roche Ltd
Qiagen N.V.
Illumina, Inc.
Oxford Nanopore Technologies
Beijing Genomics Co. Ltd.
“*” marked represents similar segmentation in other categories in the respective section.